Drug Discovery World
MAY 15, 2024
Dr Catherine Beech , CEO at Exonate and Dr Pete Adamson , CSO at Breye Therapeutics discuss the need for better therapies to treat diabetic retinal disease and current progress in the field. Specific numerical values (steps) denote the severity of NPDR, with 47-53 describing the moderately severe disease.
Drug Discovery World
JANUARY 9, 2024
Thirteen new-to-market therapeutics and drugs poised to launch in 2024 will achieve ‘blockbuster’ status by 2029 or deliver game-changing benefits to patients. The therapy has shown positive results in Phase III trials in both breast and lung cancer.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Broad Institute
MAY 9, 2024
Initially announced in March 2015, this renewed agreement extends the collaboration until September 2029 and will continue to support ongoing programs focused on the biology and genetics of aging as well as early-stage drug discovery.
Drug Discovery World
OCTOBER 4, 2022
This year’s event will cover some of the most exciting advancements in areas spanning screening, automation, high content imaging, disease models, cell and gene therapies and how innovation is being driven through partnerships and collaborations. Cell and gene therapies. In 2021, levels of investment hit an all-time high at $22.7
Vial
MARCH 1, 2024
Leading Global CROs To advance new therapies, pharma, biotech, and medical device sponsors engage CROs to help navigate the complex landscape of drug development and regulatory pathways and to manage clinical trials efficiently, ethically, and in compliance with good clinical practice ( GCP ) standards. billion by 2029.
The Pharma Data
OCTOBER 9, 2021
“While we did not achieve proof of concept in this study, we are committed to advancing our deucravacitinib clinical program in inflammatory bowel disease, including ulcerative colitis and Crohn’s disease, as well as in psoriatic arthritis, lupus and other immune-mediated diseases. About LATTICE-UC. About Ulcerative Colitis.
Expert insights. Personalized for you.
162 
Let's personalize your content